- Home
- CIB vs MRNA Comparison
CIB vs MRNA Comparison
Compare CIB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIB
- MRNA
- Stock Information
- Founded
- CIB 1945
- MRNA 2010
- Country
- CIB Colombia
- MRNA United States
- Employees
- CIB N/A
- MRNA N/A
- Industry
- CIB Commercial Banks
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIB Finance
- MRNA Health Care
- Exchange
- CIB Nasdaq
- MRNA Nasdaq
- Market Cap
- CIB 10.2B
- MRNA 10.3B
- IPO Year
- CIB 1995
- MRNA 2018
- Fundamental
- Price
- CIB $46.09
- MRNA $30.58
- Analyst Decision
- CIB Sell
- MRNA Hold
- Analyst Count
- CIB 5
- MRNA 19
- Target Price
- CIB $39.00
- MRNA $48.13
- AVG Volume (30 Days)
- CIB 349.7K
- MRNA 9.4M
- Earning Date
- CIB 08-07-2025
- MRNA 07-31-2025
- Dividend Yield
- CIB 14.21%
- MRNA N/A
- EPS Growth
- CIB 4.59
- MRNA N/A
- EPS
- CIB 1.57
- MRNA N/A
- Revenue
- CIB $5,380,508,149.00
- MRNA $3,177,000,000.00
- Revenue This Year
- CIB $21.80
- MRNA N/A
- Revenue Next Year
- CIB $5.91
- MRNA $9.70
- P/E Ratio
- CIB $7.79
- MRNA N/A
- Revenue Growth
- CIB 6.91
- MRNA N/A
- 52 Week Low
- CIB $30.25
- MRNA $23.15
- 52 Week High
- CIB $46.81
- MRNA $129.39
- Technical
- Relative Strength Index (RSI)
- CIB 65.47
- MRNA 67.68
- Support Level
- CIB $44.74
- MRNA $26.81
- Resistance Level
- CIB $46.68
- MRNA $28.24
- Average True Range (ATR)
- CIB 1.03
- MRNA 1.20
- MACD
- CIB 0.25
- MRNA 0.43
- Stochastic Oscillator
- CIB 86.64
- MRNA 91.84
About CIB BanColombia S.A.
Grupo Cibest SA formerly BanColombia SA is a financial services company. A conglomerate of financial institutions, BanColombia offers a wide range of product offerings and financial services, including loans to small and midsize enterprises and governments, leasing, factoring, and asset management. The company's operations are in Colombia, Panama, El Salvador, the United States of America, Puerto Rico, Bermuda, and Guatemala. The Bank has the following segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking and All other segments. The majority of revenue is generated from the Banking Colombia segment.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.